FDA moves to add bemotrizinol to U.S. sunscreens — Parsol Shield sunscreen could reach shelves in 2026
The FDA has proposed adding bemotrizinol (Parsol Shield) to the OTC sunscreen monograph, potentially bringing a broad‑spectrum, photostable UV filter to U.S. sunscreens — with products from DSM expected on shelves nationwide by mid‑ to late‑2026.
Key takeaways
- FDA proposed order would add bemotrizinol (INCI: bemotrizinol; chemical: bis‑ethylhexyloxyphenol methoxyphenyl triazine) to permitted OTC sunscreen active ingredients — source: FDA press announcement.
- Parsol Shield will be sold by DSM and may be used up to 6% in U.S. sunscreens, with an 18‑month exclusivity period for DSM before other makers can use it — sources: FDA press announcement; review.
- Safety profile: FDA documents cite broad UVA/UVB protection, high photostability, low irritation and minimal systemic absorption; public comment is open before any final order — see FDA press announcement.
What the FDA has done
The proposed order represents the first addition of a new UV filter to the U.S. sunscreen monograph in more than 25 years. The action follows a Tier 1 OTC Monograph Order Request (OMOR) submitted by DSM‑Firmenich, the sponsor seeking inclusion of bemotrizinol for OTC sunscreen use. If finalized, the FDA would consider bemotrizinol GRASE — generally recognized as safe and effective — for adults and children 6 months and older. Source: FDA press announcement.
Parsol Shield and DSM’s plan
DSM plans to market bemotrizinol in the U.S. under the trade name Parsol Shield. Regulatory filings and industry reporting indicate DSM will have an 18‑month exclusivity period once the ingredient is permitted, allowing it to launch products built around the filter ahead of competitors. Media coverage projects product availability in mid‑ to late‑2026, assuming the FDA completes the rulemaking on schedule. Sources: Elle; review.
Why bemotrizinol matters
Bemotrizinol is a modern organic UV filter widely used in Europe, Asia and Australia. Key advantages highlighted in regulatory and scientific reviews include:
- Broad UVA and UVB coverage, which helps protect against sunburn and long‑term photodamage — source: FDA press announcement.
- High photostability, resisting breakdown in sunlight and helping to stabilize other filters — source: review.
- Effective at low concentrations, allowing lighter, less greasy formulations that consumers may prefer — sources: Elle; review.
Safety and global use
Bemotrizinol has an established international track record. Many jurisdictions permit higher concentrations (for example, up to 10% in some EU and Asian markets). Post‑market experience in those regions has not revealed widespread safety concerns. Clinical and pharmacokinetic studies generally show low systemic absorption and mainly mild adverse effects in rare cases; one maximal‑use study found plasma levels rarely exceeded the FDA’s 0.5 ng/mL threshold. Sources: review; Elle.
Regulatory background: why it took so long
In the U.S., most sunscreens are regulated as over‑the‑counter (OTC) drugs, so active ingredients must be GRASE under the sunscreen monograph or approved via a new drug application. For years the monograph did not add many modern filters used elsewhere — a gap often attributed to regulatory inertia. The CARES Act of 2020 established the OMOR pathway, which allows companies to propose changes to OTC monographs; DSM used that route for bemotrizinol. If finalized, bemotrizinol would be the first new Category 1 GRASE UV filter added under the updated process. See FDA Q&A on monograph actions and review.
Statements from FDA leaders
“Historically moved too slowly” — FDA Commissioner Marty Makary, M.D., M.P.H., said the agency aims to modernize OTC regulation so Americans can access safe, consumer‑friendly sunscreen options. Karen Murry, M.D., acting director of the Office of Nonprescription Drugs, called bemotrizinol “a welcome addition” and said the agency hopes to accelerate bringing new active ingredients to market. Source: FDA press announcement.
What to expect next
The FDA is accepting public comment on the proposed order as part of the rulemaking process; a final determination would add bemotrizinol to OTC Monograph M020 for sunscreens if confirmed as GRASE. DSM’s Parsol Shield products could appear in U.S. stores in 2026, with wider adoption by other brands after DSM’s 18‑month exclusivity ends. Health experts continue to emphasize comprehensive sun protection: broad‑spectrum sunscreen SPF 15 or higher, reapplication every two hours, protective clothing, and shade during peak sun. Sources: FDA press announcement; review.
Context for searches and coverage
Readers are searching phrases like “FDA approves bemotrizinol sunscreen”, “new U.S. sunscreen ingredient”, and “Parsol Shield sunscreen”. Important: the agency has issued a proposed order and is still accepting public comment; the legal change is not final until after the rulemaking process. Source: FDA press announcement.
Implications for San Diego, California
Economic impact: Retailers, beach vendors and tourism businesses in San Diego could benefit from new, cosmetically friendly sunscreens that visitors prefer. Local shops and brands may stock Parsol Shield products when available.
Political consequences: County and city public‑health programs that run sun‑safety campaigns could update outreach materials to include new filters once approved.
Social and cultural effects: Bemotrizinol’s photostability and cosmetic texture may appeal to surfers, hikers and outdoor communities that value high performance without heavy residue. Sources: FDA press announcement; review.
Practical applications for residents
Until bemotrizinol products are available in the U.S., follow established sun‑safe practices: use a broad‑spectrum sunscreen SPF 15 or higher, reapply every two hours and after swimming or sweating, and combine sunscreen with protective clothing, hats and shade. When Parsol Shield or other bemotrizinol sunscreens arrive, check labels for active ingredients and follow manufacturer directions. Note the FDA’s current statement that the proposed use would be considered safe for children 6 months and older if finalized. Sources: FDA press announcement; review.
